Evotec SE (NASDAQ:EVO) Shares Purchased by DCF Advisers LLC

DCF Advisers LLC grew its holdings in Evotec SE (NASDAQ:EVO) by 5.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 229,871 shares of the company’s stock after acquiring an additional 12,816 shares during the quarter. DCF Advisers LLC owned about 0.06% of Evotec worth $956,000 at the end of the most recent reporting period.

Separately, Wellington Management Group LLP boosted its position in Evotec by 29.7% during the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock worth $9,616,000 after purchasing an additional 602,858 shares in the last quarter. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Price Performance

NASDAQ EVO opened at $3.52 on Friday. The business has a fifty day moving average of $4.16 and a 200-day moving average of $4.09. Evotec SE has a fifty-two week low of $2.85 and a fifty-two week high of $7.98. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.

Evotec Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.